CA2356551A1 - Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors - Google Patents

Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors Download PDF

Info

Publication number
CA2356551A1
CA2356551A1 CA002356551A CA2356551A CA2356551A1 CA 2356551 A1 CA2356551 A1 CA 2356551A1 CA 002356551 A CA002356551 A CA 002356551A CA 2356551 A CA2356551 A CA 2356551A CA 2356551 A1 CA2356551 A1 CA 2356551A1
Authority
CA
Canada
Prior art keywords
aav
body weight
infused
per gram
cardiomyocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002356551A
Other languages
English (en)
French (fr)
Inventor
Jeffrey M. Leiden
Eric Svensson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2356551A1 publication Critical patent/CA2356551A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002356551A 1998-12-28 1999-12-28 Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors Abandoned CA2356551A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11392398P 1998-12-28 1998-12-28
US60/113,923 1998-12-28
PCT/US1999/031093 WO2000038518A1 (en) 1998-12-28 1999-12-28 Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Publications (1)

Publication Number Publication Date
CA2356551A1 true CA2356551A1 (en) 2000-07-06

Family

ID=22352321

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002356551A Abandoned CA2356551A1 (en) 1998-12-28 1999-12-28 Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors

Country Status (5)

Country Link
EP (1) EP1139751A4 (https=)
JP (1) JP2002533359A (https=)
AU (1) AU763049B2 (https=)
CA (1) CA2356551A1 (https=)
WO (1) WO2000038518A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
CA2389524A1 (en) * 1999-11-05 2001-05-17 The Regents Of The University Of California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2419245A1 (en) * 2000-08-17 2002-02-21 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
EP1324780A4 (en) 2000-09-06 2005-06-22 Univ Johns Hopkins METHODS OF TREATING CARDIAC ARRHYTHMIA
WO2002098432A1 (en) * 2001-06-01 2002-12-12 The Brigham And Women's Hospital, Inc. Methods of treating cardiac disorders
AU2003299204A1 (en) 2002-10-02 2004-04-23 The Johns Hopkins University Focal calcium channel modulation
US20070134204A1 (en) * 2005-12-09 2007-06-14 Henrich Cheng Method for treating nerve injury and vector construct for the same
KR20090035711A (ko) * 2006-07-25 2009-04-10 셀라돈 코포레이션 유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입
KR20100129295A (ko) 2008-02-19 2010-12-08 셀라돈 코포레이션 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물
AU2012258525B2 (en) * 2011-05-26 2017-02-23 University Of Washington Cell and gene based methods to improve cardiac function
WO2019097001A1 (en) * 2017-11-16 2019-05-23 Universite D'aix-Marseille Fgf10 for the treatment of heart diseases
US12460226B2 (en) 2018-04-16 2025-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792483A (en) * 1993-04-05 1998-08-11 Vickers, Inc. Injection molding machine with an electric drive
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors

Also Published As

Publication number Publication date
WO2000038518A1 (en) 2000-07-06
AU763049B2 (en) 2003-07-10
WO2000038518A9 (en) 2002-04-11
EP1139751A4 (en) 2003-03-19
EP1139751A1 (en) 2001-10-10
JP2002533359A (ja) 2002-10-08
AU2394200A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
US7078387B1 (en) Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
CN100569297C (zh) 基因转移介导的血管形成疗法
US6936243B2 (en) Adeno-associated viral vector-mediated delivery of DNA to cells of the liver
US5962313A (en) Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US7238674B2 (en) Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
Chu et al. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors
US5792453A (en) Gene transfer-mediated angiogenesis therapy
US20060292117A1 (en) Improved rAAv vectors
JP2004313198A (ja) 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入
AU763049B2 (en) Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
WO1998024479A9 (en) Adeno-associated viral vector-mediated delivery of dna to cells of the liver
US20020159978A1 (en) Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
Giacca Virus-mediated gene transfer to induce therapeutic angiogenesis: where do we stand?
Wang et al. AAV gene transfer to the heart
EP1053025A2 (en) Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
CN101307102A (zh) 人低氧诱导因子1α重组腺病毒载体及其应用
AU2002226400B2 (en) Sequences upstream of the carp gene, vectors containing them and uses thereof
AU2002226400A1 (en) Sequences upstream of the carp gene, vectors containing them and uses thereof
US20060099183A1 (en) Use of recombinant adeno-associated virus vector (rAAV) for the prevention of smooth muscle cell proliferation in a vascular graft
AU706050C (en) Gene transfer-mediated angiogenesis therapy
Herzog et al. Improved Hepatic Gene Transfer by Using

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead